昊帆生物 (301393)
Suzhou Highfine Biotech Co., Ltd.
K-Line Chart
No K-line data available
Company NameSuzhou Haofan Biotech Co., Ltd.
Listing Date2023-07-12
Issue Price67.68RMB
Registered Capital1080010k RMB
Legal RepresentativeZhu Yong
Registered AddressNo. 1 Changting Road, Suzhou High-tech Zone, Jiangsu Province
IndustryBiological Products
Main BusinessR&D, production, and sales of peptide synthesis reagents.
Company ProfileSince its establishment, Suzhou Haofan Biotech Co., Ltd. has focused on the R&D, production, and sales of peptide synthesis reagents. Its products cover the full range of synthesis reagents used in the formation of amide bonds during the R&D and production processes of downstream small-molecule chemical drugs and peptide drugs. Meanwhile, based on customer needs and a differentiated competitive strategy, and leveraging its advantageous position in the peptide synthesis reagent industry, the company has successfully developed general-purpose molecular building blocks and protein reagents with strong technical barriers and promising market prospects, forming a product system primarily centered on peptide synthesis reagents, supplemented by general-purpose molecular building blocks and protein reagents.
Additionally, the company closely follows global drug R&D trends and aligns with the market demands of domestic and international CRO and CDMO companies. It actively expands its product pipeline in high-value-added, high-barrier specialty product areas such as liposome and lipid nanoparticle pharmaceutical reagents, ionic liquids, PROTAC reagents, and nucleotide reagents, which involve higher synthesis technical thresholds. The company is committed to providing specialty functional chemicals to global pharmaceutical R&D and manufacturing enterprises, as well as CRO and CDMO companies, to precisely and efficiently support the development of the global pharmaceutical industry.
Stock Details
1. Key Indicators
- Total Shares(W): 10800.00
- Circulating A-Shares(W): 4210.48
- Earnings Per Share(RMB): 0.9300
- Net Assets Per Share(RMB): 21.7539
- Operating Revenue(W RMB): 43469.82
- Total Profit(W RMB): 11382.68
- Net Profit Attributable to Parent(W RMB): 9923.83
- Net Profit Growth Rate(%): 3.01
- Weighted Return on Equity(%): 4.3000
- Operating Cash Flow Per Share(RMB): 0.4420
- Undistributed Profit Per Share(RMB): 4.8850
- Capital Reserve Per Share(RMB): 15.6297
2. Main Business
The main business covers:
- R&D, production, and sales of peptide synthesis reagents
3. Company Basic Information
- Company Name: Suzhou Highfine Biotech Co., Ltd.
- Listing Date: 2023-07-12
- Industry: Manufacturing of Chemical Raw Materials and Chemical Products
- Address: No. 1 Changting Road, Suzhou High-tech Zone, Jiangsu Province
- Website: www.highfine.com
- Company Profile: The company, formerly known as Suzhou Highfine Biotech Co., Ltd., was restructured into a joint-stock company in January 2016. It is primarily engaged in the R&D, production, and sales of peptide synthesis reagents.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Ningbo Haoxin Enterprise Management Consulting Partnership (Limited Partnership) | General Legal Person | 270.87 | 6.43 |
| 2 | China Universal Healthcare Mixed Securities Investment Fund | Fund | 86.68 | 2.06 |
| 3 | Suzhou Highfine Biotech Co., Ltd. Repurchase Special Securities Account | General Legal Person | 81.81 | 1.94 |
| 4 | Abu Dhabi Investment Authority - Proprietary Funds | QFII | 70.30 | 1.67 |
| 5 | Minsheng Securities - CITIC Bank - Minsheng Securities Highfine Biotech Strategic Placement No.1 Collective Asset Management Plan | Asset Management Plan | 56.81 | 1.35 |
5. Concept Sectors
- CXO Concept
- Innovative Drugs
- Weight Loss Drugs
- Margin Trading & Securities Lending
- High-Performance Stocks
- Potential for Bonus Issues
- Below IPO Price
- New QFII Holdings
- SME ChiNext
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information